Under the terms of the collaboration agreement, Suven will receive research funding and as well as potential discovery and development milestone payments in the range of $19 million to $23 million per candidate, and potential royalties on net sales of any products that may be successfully commercialized from the collaboration.
As per the collaboration agreement, Suven will be responsible for discovery activities related to the identification and selection of clinical candidates in the area of CNS, in close association with Lilly.
Venkat Jasti, CEO of Suven Life Sciences, said: “This collaboration leverages Suven’s small molecule drug discovery expertise with Lilly’s expertise and leadership position in CNS, with the goal of creating innovative products for unmet medical needs.”